{"title_page": "GW501516", "text_new": "{{short description|Chemical compound}}\n{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 458657924\n| IUPAC_name = {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid\n| image = GW501,516.svg\n| width = 270\n\n<!--Clinical data-->\n| tradename =\n| legal_AU = Scheduled as illegal from June 2018\n| legal_US = unscheduled\n| legal_UK = unscheduled\n| routes_of_administration = oral\n| pregnancy_category = N/A\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 317318-70-0\n| ATC_prefix = none\n| PubChem = 9803963\n| ChemSpiderID = 7979723\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 7I2HA1NU22\n| IUPHAR_ligand = 2687\n| ChEBI_Ref = {{ebicite|correct|EBI}}\n| ChEBI = 73726\n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 38943\n\n<!--Chemical data-->\n| C=21 | H=18 | F=3 | N=1 | O=3 | S=2 \n| molecular_weight = 453.498 g/mol\n| smiles = O=C(COc1ccc(SCc2c(C)nc(c3ccc(C(F)(F)F)cc3)s2)cc1C)O\n| StdInChI = 1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)\n| StdInChIKey = YDBLKRPLXZNVNB-UHFFFAOYSA-N\n}}\n\n'''GW501516''' (also known as '''GW-501,516''', '''GW1516''', '''GSK-516''', '''Cardarine''', and on the [[black market]] as '''Endurobol'''<ref name=convo>{{cite web|url=http://theconversation.com/anti-doping-agency-warns-cheats-on-the-health-risks-of-endurobol-12997|title=Anti-doping agency warns cheats on the health risks of Endurobol    |publisher=The Conversation|date=2013-03-22}}</ref>) is a [[Peroxisome proliferator-activated receptor delta|PPAR\u03b4]] [[receptor agonist]] that was invented in a collaboration between [[Ligand Pharmaceuticals]] and [[GlaxoSmithKline]] in the 1990s, was entered into clinical development as a drug candidate for [[Metabolic syndrome|metabolic diseases]] and [[cardiovascular diseases]], and was abandoned in 2007 because [[animal testing]] showed that the drug caused cancer to develop rapidly in several organs.<ref name=\"Sahebkar2014rev\" />\n\nIn 2007, research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a [[black market]] for the drug candidate and to its abuse by athletes as a [[performance-enhancing drugs|doping agent]]. The [[World Anti-Doping Agency]] (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.\n\n==History==\nGW501516 was initially discovered during a research collaboration between [[GlaxoSmithKline|GSK]] and [[Ligand Pharmaceuticals]] that began in 1992.<ref>{{cite news|title=GW501516 GlaxoSmithKline, Ligand milestone payment.|date=28 June 2004|publisher=R & D Focus Drug News}}</ref> The discovery of the compound was published in a 2001 issue of ''[[PNAS]]''.<ref name=\"pmid14677574\">{{cite journal | author = Wolf G | title = The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis | journal = Nutr. Rev. | volume = 61 | issue = 11 | pages = 387\u201390 |date=November 2003 | pmid = 14677574 | doi = 10.1301/nr.2003.nov.387-390 | url = https://semanticscholar.org/paper/eec262f5c1e1072eae0c393798459b2601b79fab }}</ref> Oliver ''et&nbsp;al.'' reported that they used \"[[combinatorial chemistry]] and [[structure-based drug design]]\" to develop it.<ref name=\"pmid11309497\">{{cite journal | vauthors = Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM | title = A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 98 | issue = 9 | pages = 5306\u201311 |date=April 2001 | pmid = 11309497 | pmc = 33205 | doi = 10.1073/pnas.091021198 | bibcode = 2001PNAS...98.5306O }}</ref> One of the authors was the son of [[Leo Sternbach]] who discovered [[benzodiazepines]] in the 1960s.<ref name=flynn>{{cite news|url=https://www.wsj.com/articles/0,,SB107644751774825922,00|title=Father and Son: In Two Generations, Drug Research Sees a Big Shift|publisher=The Wall Street Journal|author=Julia Flynn|date=11 February 2004}}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{cite web| url= https://sarmguide.com/cardarine-gw50156-guide/ |title= GW 50156 |date= 2017-07-18 }}</ref>\n\n''R & D Focus Drug News'' reported that GSK began [[phase I trials]] of the compound for the treatment of [[hyperlipidemia]] in 2000<ref>{{cite news|title=GW501516 Glaxo Wellcome phase change I, UK|date=20 November 2000|publisher=R & D Focus Drug News}}</ref> followed by phase I/II in 2002.<ref>{{cite news|title=GW501516 GlaxoSmithKline phase change II, UK|date=25 February 2002|publisher=R & D Focus Drug News}}</ref> In 2003, Ligand Pharmaceuticals earned a $1&nbsp;million payment as a result of GSK continuing phase I development.<ref>{{cite news|url=http://www.businesswire.com/news/home/20030604005732/en/Ligand-Earns-1-Million-Milestone-Payment-GlaxoSmithKline|title=Ligand Pharmaceuticals Incorporated Earns $1 Million Milestone Payment as GlaxoSmithKline Advances Development of 501516|date=5 June 2003|publisher=Reuters Significant Developments}}</ref>\n\nBy 2007, GW501516 had completed two phase II clinical studies and other studies relating to [[obesity]], [[diabetes]], [[dyslipidemia]] and [[cardiovascular disease]],<ref name=\"Barish_2006\">{{cite journal | vauthors = Barish GD, Narkar VA, Evans RM | title = PPAR delta: a dagger in the heart of the metabolic syndrome | journal = J. Clin. Invest. | volume = 116 | issue = 3 | pages = 590\u20137 |date=March 2006 | pmid = 16511591 | pmc = 1386117 | doi = 10.1172/JCI27955 | url =  }}</ref><ref name=\"dressel\">{{cite journal | author = Uwe Dressel | author2 = Tamara L. Allen | author3 = Jyotsna B. Pippal| author4 = Paul R. Rohde | author5 = Patrick Lau | author6 = George E. O. Musc | last-author-amp = yes| title =  The Peroxisome Proliferator-Activated Receptor \u03b2/\u03b4 Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells | journal = Molecular Endocrinology | issue =12 | pages = 2477\u201393 | year = 2003 |doi=10.1210/me.2003-0151 | url = http://mend.endojournals.org/content/17/12/2477.short |pmid=14525954 | volume = 17 }}</ref> but GSK abandoned further development of the drug in 2007 for reasons which were not disclosed at the time.<ref name=\"pmid18808307\">{{cite journal | author = Billin AN | title = PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home | journal = Expert Opin Investig Drugs | volume = 17 | issue = 10 | pages = 1465\u201371 |date=October 2008 | pmid = 18808307 | doi = 10.1517/13543784.17.10.1465 }}</ref> It later emerged that the drug was discontinued because [[animal testing]] showed that the drug caused cancer to develop rapidly in several organs, at dosages of 3 mg/kg/day in both mice and rats.<ref name=\"Sahebkar2014rev\">{{cite journal | vauthors = Sahebkar A, Chew GT, Watts GF | title = New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease | journal = Expert Opin Pharmacother | volume = 15 | issue = 4 | pages = 493\u2013503 | year = 2014 | pmid = 24428677 | doi = 10.1517/14656566.2014.876992 | quote = Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes }}</ref><ref>{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 895 - Rat carcinogenicity study with GW501516, a PPAR delta agonist | vauthors = Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ | date = 2009 | publisher = [[Society of Toxicology]] | page = 105 }}</ref><ref>{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore  | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 896 - Mouse carcinogenicity study with GW501516, a PPAR delta agonist. | vauthors = Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE | date = 2009 | publisher = [[Society of Toxicology]] | page = 105 }}</ref>\n\n[[Ronald M. Evans]]'s laboratory purchased a sample of GW501516 and gave mice a much higher dose than had been used in GSK's experiments; they found that the compound dramatically increased the physical performance of the mice. The work was published in 2007 in ''[[Cell (journal)|Cell]]'' and was widely reported in the popular press including ''The New York Times'' and ''The Wall Street Journal''.<ref name=behar>{{cite web|url=http://www.outsideonline.com/outdoor-adventure/natural-intelligence/Faster--Higher--Squeakier-.html?page=all|title=Faster. Higher. Squeakier.|publisher=Outside magazine|author=Michael Bezar|date=2011-11-01|accessdate=2013-04-02}}</ref>\n\n===Performance-enhancing drug===\nConcerns were raised prior to the [[2008 Beijing Olympics]] that GW501516 could be used by athletes as an [[ergogenic]] [[performance-enhancing drug]] that was not currently controlled by regulations or detected by standard tests. One of the main researchers from the study on enhanced endurance consequently developed a urine test to detect the drug, and made it available to the [[International Olympic Committee]]. The [[World Anti-Doping Agency]] (WADA) developed a test for GW501516 and other related [[Peroxisome proliferator-activated receptor delta|PPAR\u03b4]] modulators,<ref name=\"The Independent\">{{cite web | url = https://www.independent.co.uk/life-style/health-and-wellbeing/health-news/warning-to-beijing-olympics-over-pills-that-mimic-exercise-882608.html | title = Warning to Beijing Olympics over pills that mimic exercise | vauthors = Laurance J, Rajan A | authorlink = | date = 2008-08-01 | work = Health News, Health & Wellbeing | publisher = The Independent | pages = | accessdate = 2008-08-01 }}</ref> and added such drugs to the prohibited list in 2009.<ref>[http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf WADA 2009 Prohibited List] {{webarchive |url=https://web.archive.org/web/20090203030039/http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf |date=February 3, 2009 }}</ref>\n\nGW501516 has been promoted on [[bodybuilding]] and athletics websites<ref name=newsci>{{cite news|url=https://www.newscientist.com/article/mg21729103-400-anti-doping-agency-warns-athletes-of-black-market-drug/|title=Anti-doping agency warns athletes of black market drug |publisher=New Scientist|date=2013-03-26}}</ref> and by 2011 had already been available for some time on the [[black market]].<ref name=convo/><ref name=\"pmid21538997\">{{cite journal | vauthors = Thevis M, Geyer H, Thomas A, Sch\u00e4nzer W | title = Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet | journal = Drug Test Anal | volume = 3 | issue = 5 | pages = 331\u20136 |date=May 2011 | pmid = 21538997 | doi = 10.1002/dta.283 }}</ref> In 2011, it was reported to cost $1,000 for 10 g.<ref name=behar/>  In 2012, WADA recategorised GW501516 from a [[gene doping]] compound to a \"hormone and metabolic modulator\".<ref name=\"pmid22130396\">{{cite journal | vauthors = Sanchis-Gomar F, Lippi G | title = Telmisartan as metabolic modulator: a new perspective in sports doping? | journal = J Strength Cond Res | volume = 26 | issue = 3 | pages = 608\u201310 |date=March 2012 | pmid = 22130396 | doi = 10.1519/JSC.0b013e31824301b6 }}</ref>\n\nIn 2013, WADA took the rare step of warning potential users of the compound of the possible health risks, stating that \"clinical approval has not, and will not be given for this substance\"; the ''[[New Scientist]]'' attributed the warning to the risks of the drug causing cancer.<ref name= newsci/><ref name=wada13>{{cite web|url=https://www.wada-ama.org/en/media/news/2013-03/wada-issues-alert-on-gw501516|title=WADA issues alert on GW501516|publisher=World Anti-Doping Agency|date=2013-03-21|archiveurl=https://web.archive.org/web/20130602050612/http://playtrue.wada-ama.org/news/wada-issues-alert-on-gw501516/|archivedate=June 2, 2013}}</ref>\n\nA number of athletes have tested positive for GW501516.  At the [[Vuelta Ciclista a Costa Rica]] in December 2012, four Costa Rican riders tested positive for GW501516. Three of them received two-year suspensions, while the fourth received 12 years as it was his second doping violation.<ref>Shane Stokes: [http://www.velonation.com/News/ID/14381/GW501516-positives-confirmed-three-of-four-riders-are-from-same-BCR-Pizza-Hut-team.aspx GW501516 positives confirmed, three of four riders are from same BCR Pizza Hut team], velonation.com, 15 April 2013</ref><ref>Shane Stokes: [http://www.velonation.com/News/ID/15125/Four-riders-each-handed-two-year-bans-for-use-of-GW501516.aspx Four riders each handed two year bans for use of GW501516], velonation.com 30 July 2013</ref><ref>[http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTU3Mjg&ObjTypeCode=FILE&type=FILE&id=Nzk5OTY&LangId=1 List of sanctions] {{webarchive |url=https://web.archive.org/web/20140715214800/http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTU3Mjg&ObjTypeCode=FILE&type=FILE&id=Nzk5OTY&LangId=1 |date=July 15, 2014 }}, uci.ch</ref>  In April 2013, Russian cyclist [[Valery Kaykov]] was suspended by cycling's governing body [[Union Cycliste Internationale |UCI]] after having tested positive for GW501516. Kaykov's team [[RusVelo]] dismissed him immediately<ref>{{cite news|url=https://www.bbc.co.uk/sport/0/cycling/22111802|title=European champion Valery Kaykov sacked for failing drug test|publisher=BBC|date=2013-04-11|accessdate=2013-04-11}}</ref> and in May 2013, Venezuelan [[Miguel Ubeto]] was provisionally suspended by the Lampre team.<ref>{{cite news|url=http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|archive-url=https://archive.is/20130628075943/http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|url-status=dead|archive-date=2013-06-28|title=Miguel Ubeto Aponte provisionally suspended|publisher=UCI|date=2013-05-13|accessdate=2013-05-15}}</ref>  In February 2014, Russian race walker [[Elena Lashmanova]] tested positive for GW501516.<ref name=List20140626>[http://www.iaaf.org/download/download?filename=64099fcf-1e9a-444d-97d9-ea03d79fd4c5.pdf&urlslug=List%20of%20athletes%20currently%20serving%20a%20period%20of%20ineligibility%20as%20a%20result%20of%20an%20Anti-Doping%20Rule%20Violation%20under%20IAAF%20Rules Sanctioned athletes list \u2013 26 June 2014]</ref><ref>Associated Press: [http://sports.espn.go.com/espn/wire?section=trackandfield&id=11201932 Doping probe launched into Russian walkers], espn.com, 11 July 2014</ref> In April 2019, heavyweight boxer [[Jarrell Miller]] tested positive for GW501516 which caused his challenge for [[Anthony Joshua]]'s World Heavyweight titles to be cancelled.\n\n==Mode of action==\nGW501516 is a selective [[agonist]] (activator) of the [[peroxisome proliferator-activated receptor delta|PPAR\u03b4]] receptor.<ref name=\"pmid16625823\">{{cite journal | author = Pelton P | title = GW501516 GlaxoSmithKline/Ligand | journal = Curr Opin Investig Drugs | volume = 7 | issue = 4 | pages = 360\u201370 |date=April 2006 | pmid = 16625823 | doi = | url = }}</ref> It displays high affinity (K<sub>i</sub> = 1 nM) and potency (EC<sub>50</sub> = 1 nM) for PPAR\u03b4 with > 1,000 fold selectivity over [[PPAR\u03b1]] and [[PPAR\u03b3]].<ref name=\"pmid11309497\"/>\n\nIn rats, binding of GW501516 to PPAR\u03b4 recruits the [[coactivator (genetics)|coactivator]] [[PPARGC1A|PGC-1\u03b1]].  The PPAR\u03b4/coactivator complex in turn upregulates the expression of proteins involved in energy expenditure.<ref name=\"Sprecher_2007\"/>  Furthermore, in rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and [[type II diabetes]] was observed.  In obese rhesus monkeys, GW501516 increased [[high-density lipoprotein]] (HDL) and lowered [[very-low-density lipoprotein]] (VLDL).<ref name=\"Sprecher_2007\">{{cite journal | author = Sprecher DL | title = Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta | journal = Am. J. Cardiol. | volume = 100 | issue = 11 A | pages = n20\u20134 |date=December 2007 | pmid = 18047848 | doi = 10.1016/j.amjcard.2007.08.009 }}</ref>\n\n==See also==\n* [[Acadesine]]\n* [[GFT505]]\n* [[GW0742]]\n* [[Irisin]]\n* [[Peroxisome proliferator-activated receptor]]\n* [[Sodelglitazar]]\n* [[SR9009]]\n\n==References==\n{{Reflist|35em}}\n\n{{PPAR modulators}}\n\n[[Category:PPAR agonists]]\n[[Category:GlaxoSmithKline brands]]\n[[Category:Carcinogens]]\n[[Category:Experimental drugs]]\n[[Category:Trifluoromethyl compounds]]\n[[Category:Thioethers]]\n[[Category:Thiazoles]]\n[[Category:Carboxylic acids]]\n", "text_old": "{{short description|Chemical compound}}\n{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 458657924\n| IUPAC_name = {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid\n| image = GW501,516.svg\n| width = 270\n\n<!--Clinical data-->\n| tradename =\n| legal_AU = Scheduled as illegal from June 2018\n| legal_US = unscheduled\n| legal_UK = unscheduled\n| routes_of_administration = oral\n| pregnancy_category = N/A\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 317318-70-0\n| ATC_prefix = none\n| PubChem = 9803963\n| ChemSpiderID = 7979723\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 7I2HA1NU22\n| IUPHAR_ligand = 2687\n| ChEBI_Ref = {{ebicite|correct|EBI}}\n| ChEBI = 73726\n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 38943\n\n<!--Chemical data-->\n| C=21 | H=18 | F=3 | N=1 | O=3 | S=2 \n| molecular_weight = 453.498 g/mol\n| smiles = O=C(COc1ccc(SCc2c(C)nc(c3ccc(C(F)(F)F)cc3)s2)cc1C)O\n| StdInChI = 1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)\n| StdInChIKey = YDBLKRPLXZNVNB-UHFFFAOYSA-N\n}}\n\n'''GW501516''' (also known as '''GW-501,516''', '''GW1516''', '''GSK-516''', '''Cardarine''', and on the [[black market]] as '''Endurobol'''<ref name=convo>{{cite web|url=http://theconversation.com/anti-doping-agency-warns-cheats-on-the-health-risks-of-endurobol-12997|title=Anti-doping agency warns cheats on the health risks of Endurobol    |publisher=The Conversation|date=2013-03-22}}</ref>) is a [[Peroxisome proliferator-activated receptor delta|PPAR\u03b4]] [[receptor agonist]] that was invented in a collaboration between [[Ligand Pharmaceuticals]] and [[GlaxoSmithKline]] in the 1990s, was entered into clinical development as a drug candidate for [[Metabolic syndrome|metabolic diseases]] and [[cardiovascular diseases]], and was abandoned in 2007 because [[animal testing]] showed that the drug caused cancer to develop rapidly in several organs.<ref name=\"Sahebkar2014rev\" />\n\nIn 2007, research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a [[black market]] for the drug candidate and to its abuse by athletes as a [[performance-enhancing drugs|doping agent]]. The [[World Anti-Doping Agency]] (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.\n\n==History==\nGW501516 was initially discovered during a research collaboration between [[GlaxoSmithKline|GSK]] and [[Ligand Pharmaceuticals]] that began in 1992.<ref>{{cite news|title=GW501516 GlaxoSmithKline, Ligand milestone payment.|date=28 June 2004|publisher=R & D Focus Drug News}}</ref> The discovery of the compound was published in a 2001 issue of ''[[PNAS]]''.<ref name=\"pmid14677574\">{{cite journal | author = Wolf G | title = The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis | journal = Nutr. Rev. | volume = 61 | issue = 11 | pages = 387\u201390 |date=November 2003 | pmid = 14677574 | doi = 10.1301/nr.2003.nov.387-390 | url = https://semanticscholar.org/paper/eec262f5c1e1072eae0c393798459b2601b79fab }}</ref> Oliver ''et&nbsp;al.'' reported that they used \"[[combinatorial chemistry]] and [[structure-based drug design]]\" to develop it.<ref name=\"pmid11309497\">{{cite journal | vauthors = Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM | title = A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 98 | issue = 9 | pages = 5306\u201311 |date=April 2001 | pmid = 11309497 | pmc = 33205 | doi = 10.1073/pnas.091021198 | bibcode = 2001PNAS...98.5306O }}</ref> One of the authors was the son of [[Leo Sternbach]] who discovered [[benzodiazepines]] in the 1960s.<ref name=flynn>{{cite news|url=https://www.wsj.com/articles/0,,SB107644751774825922,00|title=Father and Son: In Two Generations, Drug Research Sees a Big Shift|publisher=The Wall Street Journal|author=Julia Flynn|date=11 February 2004}}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>\n\n''R & D Focus Drug News'' reported that GSK began [[phase I trials]] of the compound for the treatment of [[hyperlipidemia]] in 2000<ref>{{cite news|title=GW501516 Glaxo Wellcome phase change I, UK|date=20 November 2000|publisher=R & D Focus Drug News}}</ref> followed by phase I/II in 2002.<ref>{{cite news|title=GW501516 GlaxoSmithKline phase change II, UK|date=25 February 2002|publisher=R & D Focus Drug News}}</ref> In 2003, Ligand Pharmaceuticals earned a $1&nbsp;million payment as a result of GSK continuing phase I development.<ref>{{cite news|url=http://www.businesswire.com/news/home/20030604005732/en/Ligand-Earns-1-Million-Milestone-Payment-GlaxoSmithKline|title=Ligand Pharmaceuticals Incorporated Earns $1 Million Milestone Payment as GlaxoSmithKline Advances Development of 501516|date=5 June 2003|publisher=Reuters Significant Developments}}</ref>\n\nBy 2007, GW501516 had completed two phase II clinical studies and other studies relating to [[obesity]], [[diabetes]], [[dyslipidemia]] and [[cardiovascular disease]],<ref name=\"Barish_2006\">{{cite journal | vauthors = Barish GD, Narkar VA, Evans RM | title = PPAR delta: a dagger in the heart of the metabolic syndrome | journal = J. Clin. Invest. | volume = 116 | issue = 3 | pages = 590\u20137 |date=March 2006 | pmid = 16511591 | pmc = 1386117 | doi = 10.1172/JCI27955 | url =  }}</ref><ref name=\"dressel\">{{cite journal | author = Uwe Dressel | author2 = Tamara L. Allen | author3 = Jyotsna B. Pippal| author4 = Paul R. Rohde | author5 = Patrick Lau | author6 = George E. O. Musc | last-author-amp = yes| title =  The Peroxisome Proliferator-Activated Receptor \u03b2/\u03b4 Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells | journal = Molecular Endocrinology | issue =12 | pages = 2477\u201393 | year = 2003 |doi=10.1210/me.2003-0151 | url = http://mend.endojournals.org/content/17/12/2477.short |pmid=14525954 | volume = 17 }}</ref> but GSK abandoned further development of the drug in 2007 for reasons which were not disclosed at the time.<ref name=\"pmid18808307\">{{cite journal | author = Billin AN | title = PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home | journal = Expert Opin Investig Drugs | volume = 17 | issue = 10 | pages = 1465\u201371 |date=October 2008 | pmid = 18808307 | doi = 10.1517/13543784.17.10.1465 }}</ref> It later emerged that the drug was discontinued because [[animal testing]] showed that the drug caused cancer to develop rapidly in several organs, at dosages of 3 mg/kg/day in both mice and rats.<ref name=\"Sahebkar2014rev\">{{cite journal | vauthors = Sahebkar A, Chew GT, Watts GF | title = New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease | journal = Expert Opin Pharmacother | volume = 15 | issue = 4 | pages = 493\u2013503 | year = 2014 | pmid = 24428677 | doi = 10.1517/14656566.2014.876992 | quote = Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes }}</ref><ref>{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 895 - Rat carcinogenicity study with GW501516, a PPAR delta agonist | vauthors = Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ | date = 2009 | publisher = [[Society of Toxicology]] | page = 105 }}</ref><ref>{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore  | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 896 - Mouse carcinogenicity study with GW501516, a PPAR delta agonist. | vauthors = Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE | date = 2009 | publisher = [[Society of Toxicology]] | page = 105 }}</ref>\n\n[[Ronald M. Evans]]'s laboratory purchased a sample of GW501516 and gave mice a much higher dose than had been used in GSK's experiments; they found that the compound dramatically increased the physical performance of the mice. The work was published in 2007 in ''[[Cell (journal)|Cell]]'' and was widely reported in the popular press including ''The New York Times'' and ''The Wall Street Journal''.<ref name=behar>{{cite web|url=http://www.outsideonline.com/outdoor-adventure/natural-intelligence/Faster--Higher--Squeakier-.html?page=all|title=Faster. Higher. Squeakier.|publisher=Outside magazine|author=Michael Bezar|date=2011-11-01|accessdate=2013-04-02}}</ref>\n\n===Performance-enhancing drug===\nConcerns were raised prior to the [[2008 Beijing Olympics]] that GW501516 could be used by athletes as an [[ergogenic]] [[performance-enhancing drug]] that was not currently controlled by regulations or detected by standard tests. One of the main researchers from the study on enhanced endurance consequently developed a urine test to detect the drug, and made it available to the [[International Olympic Committee]]. The [[World Anti-Doping Agency]] (WADA) developed a test for GW501516 and other related [[Peroxisome proliferator-activated receptor delta|PPAR\u03b4]] modulators,<ref name=\"The Independent\">{{cite web | url = https://www.independent.co.uk/life-style/health-and-wellbeing/health-news/warning-to-beijing-olympics-over-pills-that-mimic-exercise-882608.html | title = Warning to Beijing Olympics over pills that mimic exercise | vauthors = Laurance J, Rajan A | authorlink = | date = 2008-08-01 | work = Health News, Health & Wellbeing | publisher = The Independent | pages = | accessdate = 2008-08-01 }}</ref> and added such drugs to the prohibited list in 2009.<ref>[http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf WADA 2009 Prohibited List] {{webarchive |url=https://web.archive.org/web/20090203030039/http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf |date=February 3, 2009 }}</ref>\n\nGW501516 has been promoted on [[bodybuilding]] and athletics websites<ref name=newsci>{{cite news|url=https://www.newscientist.com/article/mg21729103-400-anti-doping-agency-warns-athletes-of-black-market-drug/|title=Anti-doping agency warns athletes of black market drug |publisher=New Scientist|date=2013-03-26}}</ref> and by 2011 had already been available for some time on the [[black market]].<ref name=convo/><ref name=\"pmid21538997\">{{cite journal | vauthors = Thevis M, Geyer H, Thomas A, Sch\u00e4nzer W | title = Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet | journal = Drug Test Anal | volume = 3 | issue = 5 | pages = 331\u20136 |date=May 2011 | pmid = 21538997 | doi = 10.1002/dta.283 }}</ref> In 2011, it was reported to cost $1,000 for 10 g.<ref name=behar/>  In 2012, WADA recategorised GW501516 from a [[gene doping]] compound to a \"hormone and metabolic modulator\".<ref name=\"pmid22130396\">{{cite journal | vauthors = Sanchis-Gomar F, Lippi G | title = Telmisartan as metabolic modulator: a new perspective in sports doping? | journal = J Strength Cond Res | volume = 26 | issue = 3 | pages = 608\u201310 |date=March 2012 | pmid = 22130396 | doi = 10.1519/JSC.0b013e31824301b6 }}</ref>\n\nIn 2013, WADA took the rare step of warning potential users of the compound of the possible health risks, stating that \"clinical approval has not, and will not be given for this substance\"; the ''[[New Scientist]]'' attributed the warning to the risks of the drug causing cancer.<ref name= newsci/><ref name=wada13>{{cite web|url=https://www.wada-ama.org/en/media/news/2013-03/wada-issues-alert-on-gw501516|title=WADA issues alert on GW501516|publisher=World Anti-Doping Agency|date=2013-03-21|archiveurl=https://web.archive.org/web/20130602050612/http://playtrue.wada-ama.org/news/wada-issues-alert-on-gw501516/|archivedate=June 2, 2013}}</ref>\n\nA number of athletes have tested positive for GW501516.  At the [[Vuelta Ciclista a Costa Rica]] in December 2012, four Costa Rican riders tested positive for GW501516. Three of them received two-year suspensions, while the fourth received 12 years as it was his second doping violation.<ref>Shane Stokes: [http://www.velonation.com/News/ID/14381/GW501516-positives-confirmed-three-of-four-riders-are-from-same-BCR-Pizza-Hut-team.aspx GW501516 positives confirmed, three of four riders are from same BCR Pizza Hut team], velonation.com, 15 April 2013</ref><ref>Shane Stokes: [http://www.velonation.com/News/ID/15125/Four-riders-each-handed-two-year-bans-for-use-of-GW501516.aspx Four riders each handed two year bans for use of GW501516], velonation.com 30 July 2013</ref><ref>[http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTU3Mjg&ObjTypeCode=FILE&type=FILE&id=Nzk5OTY&LangId=1 List of sanctions] {{webarchive |url=https://web.archive.org/web/20140715214800/http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTU3Mjg&ObjTypeCode=FILE&type=FILE&id=Nzk5OTY&LangId=1 |date=July 15, 2014 }}, uci.ch</ref>  In April 2013, Russian cyclist [[Valery Kaykov]] was suspended by cycling's governing body [[Union Cycliste Internationale |UCI]] after having tested positive for GW501516. Kaykov's team [[RusVelo]] dismissed him immediately<ref>{{cite news|url=https://www.bbc.co.uk/sport/0/cycling/22111802|title=European champion Valery Kaykov sacked for failing drug test|publisher=BBC|date=2013-04-11|accessdate=2013-04-11}}</ref> and in May 2013, Venezuelan [[Miguel Ubeto]] was provisionally suspended by the Lampre team.<ref>{{cite news|url=http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|archive-url=https://archive.is/20130628075943/http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|url-status=dead|archive-date=2013-06-28|title=Miguel Ubeto Aponte provisionally suspended|publisher=UCI|date=2013-05-13|accessdate=2013-05-15}}</ref>  In February 2014, Russian race walker [[Elena Lashmanova]] tested positive for GW501516.<ref name=List20140626>[http://www.iaaf.org/download/download?filename=64099fcf-1e9a-444d-97d9-ea03d79fd4c5.pdf&urlslug=List%20of%20athletes%20currently%20serving%20a%20period%20of%20ineligibility%20as%20a%20result%20of%20an%20Anti-Doping%20Rule%20Violation%20under%20IAAF%20Rules Sanctioned athletes list \u2013 26 June 2014]</ref><ref>Associated Press: [http://sports.espn.go.com/espn/wire?section=trackandfield&id=11201932 Doping probe launched into Russian walkers], espn.com, 11 July 2014</ref> In April 2019, heavyweight boxer [[Jarrell Miller]] tested positive for GW501516 which caused his challenge for [[Anthony Joshua]]'s World Heavyweight titles to be cancelled.\n\n==Mode of action==\nGW501516 is a selective [[agonist]] (activator) of the [[peroxisome proliferator-activated receptor delta|PPAR\u03b4]] receptor.<ref name=\"pmid16625823\">{{cite journal | author = Pelton P | title = GW501516 GlaxoSmithKline/Ligand | journal = Curr Opin Investig Drugs | volume = 7 | issue = 4 | pages = 360\u201370 |date=April 2006 | pmid = 16625823 | doi = | url = }}</ref> It displays high affinity (K<sub>i</sub> = 1 nM) and potency (EC<sub>50</sub> = 1 nM) for PPAR\u03b4 with > 1,000 fold selectivity over [[PPAR\u03b1]] and [[PPAR\u03b3]].<ref name=\"pmid11309497\"/>\n\nIn rats, binding of GW501516 to PPAR\u03b4 recruits the [[coactivator (genetics)|coactivator]] [[PPARGC1A|PGC-1\u03b1]].  The PPAR\u03b4/coactivator complex in turn upregulates the expression of proteins involved in energy expenditure.<ref name=\"Sprecher_2007\"/>  Furthermore, in rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and [[type II diabetes]] was observed.  In obese rhesus monkeys, GW501516 increased [[high-density lipoprotein]] (HDL) and lowered [[very-low-density lipoprotein]] (VLDL).<ref name=\"Sprecher_2007\">{{cite journal | author = Sprecher DL | title = Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta | journal = Am. J. Cardiol. | volume = 100 | issue = 11 A | pages = n20\u20134 |date=December 2007 | pmid = 18047848 | doi = 10.1016/j.amjcard.2007.08.009 }}</ref>\n\n==See also==\n* [[Acadesine]]\n* [[GFT505]]\n* [[GW0742]]\n* [[Irisin]]\n* [[Peroxisome proliferator-activated receptor]]\n* [[Sodelglitazar]]\n* [[SR9009]]\n\n==References==\n{{Reflist|35em}}\n\n{{PPAR modulators}}\n\n[[Category:PPAR agonists]]\n[[Category:GlaxoSmithKline brands]]\n[[Category:Carcinogens]]\n[[Category:Experimental drugs]]\n[[Category:Trifluoromethyl compounds]]\n[[Category:Thioethers]]\n[[Category:Thiazoles]]\n[[Category:Carboxylic acids]]\n", "name_user": "BobTheSnail99", "label": "unsafe", "comment": "(\u2192\u200eHistory)", "url_page": "//en.wikipedia.org/wiki/GW501516"}
